MoonLake conducted a positive final pre-BLA (Biologics License Application) meeting with the U.S. Food and Drug Administration (FDA), where ...
MoonLake Immunotherapeutics MLTX shares are up during Monday’s trading session, trading higher as the company is reporting ...
Investor's Business Daily on MSN
MoonLake clears a key regulatory hurdle, and shares rocket
Shares of MoonLake Immunotherapeutics bounded higher Monday after the biotech said it met with the Food and Drug ...
NANTES, France--(BUSINESS WIRE)--Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that first Phase 1 results for BI 770371, a novel anti-SIRPα monoclonal ...
MoonLake Immunotherapeutics (NASDAQ:MLTX) shares rose more than 4% in premarket trading on Monday after the biotechnology ...
Nantes, France, April 23, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company ...
View MoonLake Immunotherapeutics Class A MLTX stock quote prices, financial information, real-time forecasts, and company news from CNN.
Focused on immunology therapies, this clinical-stage biotech reported significant insider selling amid a challenging year for the stock.
OSE entered 2026 with a clear 3-year strategic roadmap focused on delivering multiple catalysts for both lusvertikimab and Tedopi® 1; €22.7 and €17.0 million cash position as ...
JERUSALEM , Jan. 4, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation and immunology (I&I) biological products, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results